Kornimate/medical-research-clean huggingface dataset:
conventional repetitive transcranial magnetic stimulation for tinnitus treatment

Conditions: Chronic Tinnitus

Summary: the objective of the investigators study is to assess conventional repetitive transcranial magnetic stimulation (rtms) in patients with chronic severe tinnitus. a randomized, double-blind, sham-controlled procedure, with four increasing levels of magnetic "pseudo-dose" has been designed, in order to characterize the effectiveness of rtms while controlling its safety and tolerability. by combining various rtms protocols with a twelve-month follow-up, and using an effect modeling, the study aims at: (i) specify the effective values of rtms parameters, with an adequate tolerance; (ii) determine the expected benefit and the persistence of effect; (iii) assess the practical feasibility of this kind of therapeutic management.


Eligibility criteria:
inclusion criteria: * men and women between the ages of 18 and 75 years old; * adequate medical condition (asa p1 or p2 in physical status classification system); * disabling tinnitus (stss \> 8/16 or thq \> 50%), with the following characteristics: continuous, subjective, non-pulsatile; unilateral (or bilateral with unilateral predominance), chronic (duration for at least one year), refractory for usual treatments taken for at least six months; * naive regarding tms; * able to provide informed consent. exclusion criteria: * objective tinnitus or tinnitus with treatable cause; * presence of intracranial or intraocular ferromagnetic materiel or particles (with the exception of dental fillings and mri-compatible stapedectomy prosthesis); * cardiac pacemaker or other electronic implants (including cochlear implant); * serious heart disease or other unstable major medical condition; * personal history of central nervous system disorder, head injury, stroke or seizures (including childhood febrile seizures); * familial history of epilepsy; * concomitant medication with antidepressants and antipsychotics; * possibility of pregnancy; * known claustrophobia; * others known contraindications to rtms or brain mri; * refusal to be informed about the results of anatomical mri

Keywords: neuro-otology chronic tinnitus sensory disability repetitive transcranial magnetic stimulation dose escalation
telerehabilitation through serious games in virtual reality in a stroke population (autorrevi)

Conditions: Stroke; Hemiparesis; Cognitive Impairment; Healthy Subjects

Summary: after a stroke, individuals present with motor and/or cognitive impairments. these impairments limit activity, restrict participation and affect quality of life. therefore, rehabilitation programs are provided from the earliest days. however, an important proportion of patients do not achieve the recommended amount of rehabilitation therapy (even in institutional systems). in fact, patients do not always have access to healthcare systems. moreover, hospital resources and healthcare systems are often limited (especially in poor countries) which has led to the development of new cost-effective rehabilitation methods such as self-rehabilitation and tele-rehabilitation. this study aims : 1. to develop and validate relevant self-assessments tools in virtual reality 2. to propose auto-adaptative virtual reality-based therapies based on the link between motor and cognitive functions.


Eligibility criteria:
inclusion criteria: * stroke patients (with hemiparesis or cognitive impairment such as apraxia, aphasia or hemineglect) or healthy subjects * able to undersand simple instructions exclusion criteria: * other disease that could affect upper limb motor function or cognition
kanagawa intravenous and endvascular treatment registry

Conditions: Acute Ischemic Stroke

Summary: the k-net registry is a prospective, multicenter, observational registry study for all consecutive patients who received intravenous tpa therapy and/or endovascular treatment for acute ischemic stroke. this study is attended by 40 of the 58 primary stroke centers in kanagawa prefecture, which is located in the tokyo metropolitan area and has a population of 9.24 million. patient enrollment for this study began in january 2018.

inclusion criteria for this study are all consecutive patients who meet either or both of the patients who received intravenous tpa therapy for acute ischemic stroke and intention to perform evt for large vessel occlusion. there were no exclusion criteria. the local neurologists, neurosurgeons, and neurointerventionalists at each institution made the decision to perform evt and intravenous tpa. the primary outcome was good as defined by the modified rankin scale (mrs) of 0 to 2 at three months. we also determined a favorable outcome: mrs 0-2 or not worsening of the mrs score at three months. secondary analyses included predicting a favorable outcome using multivariate logistic regression analysis.

Eligibility criteria:
inclusion criteria: inclusion criteria for this study are all consecutive patients who meet either or both of the patients who received intravenous tpa therapy for acute ischemic stroke and intention to perform evt for large vessel occlusion. exclusion criteria: there were no exclusion criteria. there are no upper or lower age limits for this study.

Keywords: acute stroke, mechanical thrombectomy, intravenous tpa
hemodynamic survey cardiac surgical scenarios

Conditions: Low Cardiac Output

Summary: the purpose of this study is to find out the lidco rapid ( monitoring tool gives cardiac output) is as equivalent in determining the hemodynamic assessment in cardiac surgical scenarios as the most often used pulmonary artery catheter, which is much more invasive than the lidco rapid. this will be accomplished through online surveys which have different cardiac surgery scenarios and will be distributed to cardiac fellowship trained anesthesiologists. the online based survey will include a specific scenario and details on the scenario represented in image format and a brief description of the patient to aid with their analysis of the situation.

data from pa catheter such as pa pressure, pulmonary wedge pressure and cardiac output has been widely used in the various clinical situations warranting advance hemodynamic monitoring. it is considered as gold standard but unfortunately there is always risk associated with pa catheter and time lag between the clinical events and interpretation. lidco rapid is one of the non-invasive hemodynamic tools to measure various parameters. it is widely used in the intensive care set up for goal directed therapy but unfortunately there is not enough data to show whether it is useful in various peri-operative clinical conditions. in the online based survey, responses from the participants are recorded in the nominal scale ( 1 to 5 where 3 represents near normal). this survey will help to determine whether investigators can replace the lidco in any clinical situation warranting advance hemodynamic monitoring. no previous study was done to specifically find out the hemodynamic component that differs between these tools intraoperatively in varying hemodynamic conditions during cardiac surgery although there were few studies compared the trend in the cardiac output with difference in opinion on their accuracy.

Eligibility criteria:
inclusion criteria: * must be a certified anesthesiologist with cardiac fellowship training exclusion criteria: * none
a multi-center trial to determine the safety and efficacy of lx1033 in subjects with diarrhea-predominant irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the objective of this study is to evaluate the safety and efficacy of lx1033 over a range of dose levels in subjects with diarrhea-predominant irritable bowel syndrome (ibs).


Eligibility criteria:
inclusion criteria: * male and female subjects, aged 18 to 70 years, with diarrhea-predominant ibs (ibs-d) with symptom onset at least 6 months prior to diagnosis * two or more days per week with at least one stool with a consistency of type 6 or 7 (bristol stool form scale) * weekly average of worst abdominal pain in past 24 hours score of greater than or equal to 3.0 using a 0-10 point scale * ability to provide written, informed consent exclusion criteria: * inability to discontinue any current drug therapy for ibs, with the exception of bulking agents. subjects will be allowed up to 2 doses of loperamide per week as rescue medication. * subjects who score severe abdominal pain (rated 7 or higher) 5 or more days per week * concomitant use of opioid analgesic drugs or drugs that affect bowel motility * any abnormalities or conditions deemed by the investigator as clinically significant
bracing or kinesio taping in the management of lateral epicondylitis

Conditions: Lateral Epicondylitis (Tennis Elbow)

Summary: lateral epicondylitis is an overuse syndrome of the forearm, which is associated with pain and sensitivity in the lateral elbow region. the aim of the study was to find out about is there any difference between the effects of traditional orthotic devices and adhesive taping, in the management of lateral epicondylitis. therefore, the forearm counterforce brace, which was widely used in daily clinical practice for lateral epicondylitis, was compared with kinesio tape, a new technique of adhesive taping which has become increasingly popular. the study investigated and compared the effects of the two interventions (the forearm counterforce brace and kinesio tape) on pain severity, functional status and disability of patients with lateral epicondylitis.


Eligibility criteria:
inclusion criteria: * aged between 18 and 65 years * presence of elbow pain lasting for less than three months exclusion criteria: * history of acute trauma or fracture on forearm * congenital or acquired elbow deformities * demyelinating diseases * patients who had diagnosed as fibromyalgia * presence of skin lesion on lateral aspect of the elbow * presence of rheumatic disease * presence of systemic infection * presence of pregnancy * presence of malignancy

Keywords: lateral epicondylitis forearm counterforce brace kinesio taping
cohort event monitoring for dengvaxia®, cyd-tdv dengue vaccine

Conditions: Dengue Fever; Dengue Hemorrhagic Fever

Summary: the aim of this study is to evaluate the safety profile of dengvaxia® when used in the real-world immunization setting primary objective: * to measure the incidence of selected adverse events (aes) and serious aes (saes) occurring over a period of six (6) months after each dengvaxia® dose administration; * to quantify the association between dengvaxia® and each of the selected aes and saes for which a risk window after vaccination can be defined, using estimates of relative risk * to monitor the occurrence and frequency of hospitalized dengue disease as well as any other saes leading to hospitalization or death, including new and previously unrecognized saes, following dengvaxia® administration on a longer term (up to 5 years after the first dengvaxia® dose administration. secondary objectives: * to identify risk factors for hospitalized dengue disease (severe or not) among subjects vaccinated with dengvaxia®; * to describe the frequency of hospitalized dengue disease and/or other saes or selected aes according to the number of dengvaxia® doses and/or interval between doses.

this is a prospective multi-national non-interventional study that includes two components of cohort event monitoring (i) short-term safety surveillance with a follow-up of 6 months after each dengvaxia® dose administration and (ii) a long-term safety surveillance with a follow-up of five years after the first dose. no vaccine will be provided as part of this study. study population will be identified in a convenient sample of sites as representative as possible of vaccination centers in each country. subjects who received their first dose of dengvaxia® at participating sites during the recruitment period and who meet the eligibility criteria will be asked to participate. after enrollment, vaccinees will be contacted periodically by telephone, e-mail, or short message service (sms) during follow-up for the identification of outcomes and dengvaxia® vaccination status.

Eligibility criteria:
inclusion criteria: * subjects who received the first dose of dengvaxia® across all age groups, even if vaccination was given outside of local specific label indications or recommendations * informed consent form (icf) or assent form (af) has been signed and dated by the subject (based on local regulations), and/or icf has been signed and dated by the parent(s) or another legal acceptable representative (and by an independent witness if required by local regulations) * subjects for whom a telephone contact or an e-mail address is available. exclusion criteria: * none

Keywords: dengue fever dengue hemorrhagic fever dengvaxia®
evaluation of four different dosing regimens of cross-linked polyelectrolyte (clp) in healthy volunteers

Conditions: Healthy

Summary: this is a study to determine the effect of four different dosing regimens of clp in normal healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy volunteer is ≥ 18 years of age with bmi of 18-32 * females could not be pregnant or breast feeding and had to be using birth control * must have regular bowel habits, typically producing at least 1 daily bowel movement exclusion criteria: * screening 12-lead ecg demonstrating qtc interval \>430 msec for males and \>450 msec for females, or any cardiac rhythm disorder considered by the investigator to be clinically relevant * history or presence of gastrointestinal conditions * positive drug screen for substances of abuse * positive results for hiv, hepatitis b, or hepatitis c

Keywords: basic science safety tolerability efficacy of clp
flexibility, efficacy, and safety of a foldable capsular vitreous body in the treatment of severe retinal detachment

Conditions: Retinal Detachment

Summary: the purpose of this study is to determine the feasibility, primary safety and efficacy of foldable capsular vitreous body (fcvb) in the treatment of retinal detachment, based on the multi-center clinical trial.

previous clinical trial have demonstrated that foldable artificial vitreous body (fcvb),with balanced salt solution (bss) filled in 11 patients during three-months observation,or silicone oil filled in 4 patients during a six-month observation respectively, can be transplanted into the vitreous body easily, and performances good safety and efficacy in the treatment of severe retinal detachment. current multi-center clinical trial was to determine the feasibility, primary safety and efficacy of fcvb with silicone oil filled in the treatment of retinal detachment in 120 patients.

Eligibility criteria:
inclusion criteria: 1. age range from 18 to 65, refractive error less than ±3d 2. corrected visual acuity less than 0.05 3. ocular axial length is 16 to 25mm 4. severe retinal detachment that can not be treated by current artificial vitreous body: 1. severe unilateral ocular perforating injuries, compounded retinal or choroidal detachments resulted from retinal rupture or retinal choroidal hemorrhage. 2. severe unilateral ocular rupture injuries result in retina or choroid defect. 3. giant posterior scleral rupture injuries that can not be repaired. 4. silicone oil can't be taken out for a long time with incomplete reattachment. 5. participants have undergone retinal detachment surgery and silicone oil tamponade twice or more, however, retina is re-detachment after silicone oil removal. 5. participants can understand the aim of this clinical trial and sign the informed consent form exclusion criteria: 1. participants have a silica gel allergy or scar diathesis 2. entophthalmia 3. uveitis 4. the contralateral eye suffered from intraocular surgery 5. uncontrollable the other eye diseases 6. corrected visual acuity of contralateral eye less than 0.4 7. proliferative diabetic retinopathy 8. the lens of target eye is transparent 9. serious heart, lung, liver and kidney dysfunction 10. pregnancy, preparation for pregnancy during clinical trial and breast-feeding female 11. drug abuse or alcoholism 12. participated the other drug or medical devices clinical trial before screening of this trial 13. any research doctors consider that the condition of participants will hinder the clinical trial--prone to mental stress, loss control of mood, depression etc. 14. patient adherence is so poor that study procedures can not be finished

Keywords: vitreous body substitute foldable capsular vitreous body
effects of olfactory training on the brain function in t2dm patients with mild cognitive impairment

Conditions: Type 2 Diabetes Mellitus; Mild Cognitive Impairment

Summary: this is a prospective, randomized, open label, parallel, 4-month study to explore and evaluate the therapeutic effects of olfactory training on the cognitive function, olfactory function, and odor-induced brain activation in t2dm patients with mild cognitive impairment (mci).


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus; * aged: 40 -75 years ; * cognitive function assessment suggests mild cognitive impairment; * a stable glucose-lowering regimen for more than 2 months; * ≥6 years of education; * right-handed. exclusion criteria: * cognitive function assessment suggests normal cognition or dementia; * other dementia related neurological diseases or depression, mental dysplasia, mania, schizophrenia, etc in the past 2 years; central nervous system diseases, including brain trauma, intracranial hemorrhage, acute cerebral infarction, etc; * severe sinusitis, nasal cavity and sinus polyps, skull base or nasopharyngeal tumors and other space occupying lesions; * congenital diseases and traumatic history of nose, maxillofacial and skull base affecting olfaction. * with symptoms of upper respiratory tract infection, including nasal congestion, runny nose, fever, etc. on the day of mr examination; * diabetic acute and chronic complications, including diabetic ketoacidosis, diabetic ketoacidosis; a hyperglycemic hyperosmolar state or severe hypoglycemic coma, etc. * severe impairment of heart, liver, kidney and other organs; * contraindications of mri examination, such as implantation of metal prosthesis in vivo, claustrophobia, etc; * pregnant and lactating women; * receive other test drugs currently or within 3 months before participating in the project; * known or suspected allergic history to essential oil; * taking cognitive-related drugs.

Keywords: functional mri cognition olfactory training
surgical treatment of adult trigger finger

Conditions: Trigger Finger

Summary: trigger finger is a condition commonly treated with surgical intervention, yet no specific incision type has been associated with improved or worsened scar quality or outcome. therefore, the investigators objective is to determine if the incision type may affect the results of operative treatment of trigger finger. therefore, the goals of this study are as follows: primary objective: to directly compare incision type (transverse vs. longitudinal) for trigger finger release with scar quality and patient satisfaction via a validated scar evaluation scale. secondary objective: to directly compare incision type (transverse vs. longitudinal) for trigger finger release to patient outcome via a validated upper extremity outcome score.


Eligibility criteria:
inclusion criteria: * all patients over the age of 18 presenting to the four attending surgeons (don coleman, douglas hutchinson, andrew tyser, angela wang) through either the university of utah orthopaedic center or the veteran affairs hospital will be evaluated for possible inclusion into the study * patients who fail conservative treatment and elect to proceed with open surgical release of the a1 pulley will be offered the option of being included in the study. exclusion criteria: * patients aged less than 18, previous failed surgical a1 pulley release, and patients receiving their care outside of the university of utah hospital system or the veteran affairs hospital * in addition, this study will evaluate trigger finger release; patients receiving treatment for trigger thumb will be excluded

Keywords: trigger finger prospective clinical research randomized questionnaires transverse longitudinal
relation between renin-angiotensin gene polymorphisms, plasma adiponectin and arterial stiffness in renal transplant recipients

Conditions: Vascular Diseases; Arterial Stiffness

Summary: relation between renin-angiotensin gene polymorphisms, plasma adiponectin and arterial stiffness in renal transplant recipients


Eligibility criteria:
inclusion criteria: * aged between 18 and 80 years, extremes included * kidney transplants with or without other transplant organs * informed consent * stable clinical condition on the basis of a pre-trial physical examination, medical history, and the results of blood biochemistry and haematology tests exclusion criteria: * pregnant, lactating females * recent (\< 4 weeks) change in antihypertensive drug medication * current or recent (\< 2 weeks) acute illness such as infection or bleeding * current treatment for malignancy
a study to learn about the study medicine called pf-08046031 in advanced melanoma and other solid tumors

Conditions: Malignant Melanoma; Melanoma; Metastatic Melanoma; Solid Tumors

Summary: this study will test the safety of a drug called pf-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body. it will also study the side effects of this drug. a side effect is anything a drug does to the body besides treating the disease. the study will have 3 parts. part a and b of the study will find out how much pf-08046031 should be given to participants. part c will use the information from parts a and b to see if pf-08046031 is safe and if it works to treat solid tumor cancers.


Eligibility criteria:
inclusion criteria: * participants in part 1 (dose escalation) must have histologically- or cytologically-confirmed metastatic or unresectable cutaneous melanoma. they must have progressive disease following at least 1 prior anti programmed death-1 (pd 1)/programmed death-ligand 1 (pd l1) immunotherapy containing regimen (either as monotherapy, or in combination with other checkpoint inhibitors or other therapies) and should have no appropriate standard therapy available at the time of enrollment in the judgment of the investigator. * participants in part 2 (dose optimization) must have histologically- or cytologically-confirmed metastatic or unresectable cutaneous melanoma. they must have progressive disease following at least 1 prior anti pd 1/pd l1 immunotherapy containing regimen (either as monotherapy, or in combination with other checkpoint inhibitors or other therapies) but not more than 2 total prior lines of systemic therapy. * for part 3 (dose expansion): participants must have histologically- or cytologically confirmed metastatic or unresectable solid malignancy from 1 of the following tumor types: cutaneous melanoma, nsclc, hnscc, esophageal cancer. eastern cooperative oncology group (ecog) performance status score of 0 or 1 measurable disease per recist v1.1 at baseline exclusion criteria: active cerebral/meningeal disease related to the underlying malignancy. previous exposure to cd228-targeted therapy, vedotin or an mmae-containing agent, or any taxane containing regimen for advanced disease. melanoma subtypes including uveal, and mucosal are excluded. chemotherapy, definitive radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of study intervention, or within 2 weeks prior to first dose of study intervention if the underlying disease has progressed on treatment other protocol specific criteria might apply. -

Keywords: solid tumors other solid tumors